1%替瑞布林软膏的皮肤美白功效。
The Skin-Lightening Power of Tirbanibulin 1% Ointment.
作者信息
Li Pomi Federica, d'Aloja Andrea, Rottura Michelangelo, Vaccaro Mario, Borgia Francesco
机构信息
Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, 90127, Palermo, Italy.
Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.
出版信息
Dermatol Ther (Heidelb). 2025 Jan;15(1):95-110. doi: 10.1007/s13555-024-01310-0. Epub 2024 Nov 30.
BACKGROUND
Tirbanibulin 1% ointment has been licensed to treat non-hyperkeratotic actinic keratosis (AK) on the face and scalp in adults. Recent evidence suggests that, besides the antineoplastic effect, tirbanibulin may also confer substantial cosmetic benefits to patients.
METHODS
We report a single-center retrospective study of patients affected by solar lentigines (SLs) and AKs in the context of field cancerization treated with tirbanibulin 1% ointment.
RESULTS
Among 42 patients, 35% (n = 15) experienced complete clearance of SLs, while partial clearance was observed in 50% (n = 21) of patients. Regarding AKs, complete and partial clearance were observed in 52% (n = 22) and 40% (n = 17) of patients, respectively. Major study limitations are the small sample size and the absence of a control group.
CONCLUSIONS
Our results suggest that tirbanibulin 1% ointment may offer the dual benefit of treating AKs while simultaneously lightening aesthetically bothersome and difficult-to-treat lesions like SLs with just 5 days of application.
背景
1%替瑞布林软膏已获许可用于治疗成人面部和头皮的非角化过度性光化性角化病（AK）。最近的证据表明，除了抗肿瘤作用外，替瑞布林还可能给患者带来显著的美容益处。
方法
我们报告了一项单中心回顾性研究，该研究针对在现场癌变背景下患有日光性雀斑（SL）和AK且接受1%替瑞布林软膏治疗的患者。
结果
在42例患者中，35%（n = 15）的患者SL完全清除，50%（n = 21）的患者部分清除。关于AK，分别有52%（n = 22）和40%（n = 17）的患者完全清除和部分清除。主要研究局限性在于样本量小且缺乏对照组。
结论
我们的结果表明，1%替瑞布林软膏可能具有双重益处，即仅应用5天即可在治疗AK的同时减轻像SL这样在美学上令人烦恼且难以治疗的病变。
Zotero 插件